Rallybio Announces Reverse Merger with Candid Therapeutics and $505.5M Financing, Existing Shareholders Heavily Diluted

summarizeSummary

Rallybio Corp announced a definitive agreement for a reverse merger with private Candid Therapeutics, Inc., which will result in existing Rallybio shareholders owning only 3.65% of the combined company, alongside a $505.5 million concurrent financing for Candid.

check_boxKey Events

• Reverse Merger Agreement

  Rallybio will acquire Candid Therapeutics in a reverse merger, with Candid surviving as a wholly-owned subsidiary. The combined company will be renamed Candid Therapeutics, Inc. and trade under 'CDRX'.

• Extreme Shareholder Dilution

  Pre-merger Rallybio equityholders are expected to own only approximately 3.65% of the combined company on a fully diluted basis.

• Substantial Concurrent Financing

  Candid secured over $505.5 million in private financing from institutional investors, expected to fund the combined company through 2030.

• Complete Leadership Change

  Candid's CEO, Ken Song, will lead the combined company, and current Rallybio executive officers and directors are expected to resign.

auto_awesomeAnalysis

This is a transformational reverse merger where Rallybio, a public company, is effectively being acquired by Candid Therapeutics, a private clinical-stage biotechnology company. The transaction will lead to a complete change in Rallybio's business focus, management, and board. Existing Rallybio shareholders will experience extreme dilution, retaining only approximately 3.65% ownership of the combined entity, while Candid's pre-merger equityholders and new investors from a $505.5 million concurrent financing will control the vast majority. The financing is substantial, representing over 900% of Rallybio's current market capitalization, and is expected to fund the combined company's operations through 2030, providing a new, well-capitalized path forward. Rallybio's prior assets will be spun off into Contingent Value Rights (CVRs) for existing shareholders, further signaling the end of Rallybio's previous business. This strategic pivot follows Rallybio's recent 1-for-8 reverse stock split (effective February 6, 2026) to regain Nasdaq compliance, leveraging its public listing for a new corporate direction. The merger values Rallybio at approximately $8.98 per share, a discount to its current trading price of $9.82, which is near its 52-week high.